Generic Name and Formulations:
Methylphenidate HCl 20mg; ext-rel tabs; dye-free; contains sucrose.
Adults and Children:
Swallow whole. <6yrs: not established. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
Indications for METADATE ER:
Adults and Children:
Swallow whole. <6yrs: not recommended. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Severe hypertension. Angina. Cardiac arrhythmias. Heart failure. Recent MI. Hyperthyroidism. Thyrotoxicosis. Glaucoma. Surgery. History of tics or Tourette's syndrome in patient or family.
History of drug dependence or alcoholism; monitor. Structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems: not recommended. Pre-existing hypertension. Assess cardiovascular status. Psychosis. Bipolar disorder. Mania. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. Risk of peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth, HR, BP, CBC, differential, and platelet counts. Interrupt therapy if growth suppression occurs. Reduce dose or discontinue if paradoxical worsening of symptoms occur. Re-evaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid alcohol. Caution with pressor agents. May potentiate anticonvulsants (eg, phenobarbital, phenytoin, primidone), oral anticoagulants, tricyclics, SSRIs, phenylbutazone. May be affected by agents that alter urinary pH.
Headache, anorexia, abdominal pain, dizziness, rash, insomnia, nervousness, blood dyscrasias, weight loss, nausea, dyskinesias, tachycardia, arrhythmias; priapism, Tourette's syndrome, toxic psychosis, seizures, hypertension, visual disturbances.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds